Skip to main content

Table 3 summary of the studies with inconclusive results about the use of IVIG in COVID-19

From: Potential therapeutic approach of intravenous immunoglobulin against COVID-19

Studies with inconsistent results Type of Study Number of Cases Dosage of IVIG Measurement of treatment success Other therapies used in the course of disease Comorbidities Additional Explanations
Shao et al. [40] multicenter retrospective cohort 325 0.1 to 0.5 g/kg per day for 5 to 15 days 28 day mortality, 60 day mortality, length of hospital stay, length of disease period Supportive care Varied IVIG therapy cannot reduce the total duration of the disease, only patients with severe COVID-19 from the IVIG group had better 28-day mortality rates
Tabarsi et al. [54] Randomized control trial 84 400 mg/kg/day for three days In hospital mortality rate, mechanical ventilation need, length of hospital stay hydroxychloroquine, lopinavir/ritonavir and supportive care Varied No improvement in CT scan or the overall course of the disease was observed despite a reduction in the duration of hospitalization